Expedite Your Early Phase Clinical Trial Decisions

Accelerate determining your molecule's potential — even in the most complex study designs

In the current landscape of high drug development costs, designing efficient early-phase clinical trials is critical. The right CRO partner can provide key input on trial designs based on preclinical data — including adaptive and seamless trial designs and patient-centric designs. It also essential to choose a CRO that has an extensive global capacity to quickly and efficiently identify the right subjects, dose/exposure, therapeutic response, and overall commercial strategy.

Leading the industry in customized, best-in-class mixed-design concepts

Whether it's a simple study with healthy volunteers or a highly complex protocol involving patients (or both), IQVIA experts will ensure your design and delivery is optimally suited for your molecule while maximizing safety, quality, speed and efficiency. Our industry-leading network of 41 medically-assessed and qualified early phase clinical units — including IQVIA's own early phase unit in the UK — leverages IQVIA's data assets spanning 80 countries and 6 continents in virtually every therapeutic indication.

Over the last 5 years

536	Early phase studies in 28,122 patients across 67 countries
151	First-in-human studies in 13,038 subjects across 48 countries
327	Early phase studies in 14,012 healthy adult volunteers across 48 countries

IQVIA's Global Reach: An Extensive Range of Strategically Placed, Therapeutically Aligned Sites

2,424 Global bed capacity	**41** Phase I GxP – medically qualified in-network sites	**>116** Early phase project managers	**>2300** Early phase experienced monitors

GLOBAL DRUG DEVELOPMENT EXPERTISE	• Therapeutic, scientific and regulatory knowledge covering all stages of drug development • > 15 Therapeutic and Specialty Centers of Excellence (CoE) across a wide range of medical domains, including a dedicated early phase CoE • Access to IQVIA's worldwide database and assets, accelerating patient identification by querying > 30 million electronic health records (EHRs)
INDUSTRY LEADERS IN PHASE I HYBRID DESIGNS	• Single and multi-site early phase healthy volunteer, hybrid and patient studies tailored to your unique needs • Fully dedicated team of Clinical Pharmacology experts – scientists, medics, project managers, medical writers • Robust data management, biostatistics and pharmacokinetics / pharmacodynamics (PK/PD) expertise
GLOBAL SITE NETWORK SPANNNG 6 CONTINENTS	• Work with our own site in the UK, a selective network of trusted partner sites, and 3rd party sites • Vast access to diverse, therapeutically aligned sites including APAC and Australia • An unwavering focus on safety and quality led by our Medical and Scientific Safety Review Group (MSRG)
SEAMLESS TRANSITION FROM EARLY TO LATE STAGE TRIALS	• Integrated phase I-IIa delivery model that maximizes efficiency and expedites molecule advancement • Delivers continuity through one SOP, one platform, one project manager and retains institutional knowledge • Accelerates and simplifies advancing your molecule to the next phase, from first-in-human studies all the way to marketing authorization

The benefits of working with IQVIA

- **Reach faster and better-informed go/no-go decisions** with our expertise and best-in-class predictive models such as PK/ PD modeling and simulation, early QT/C-QT analysis, biomarkers and other specialized techniques
- **Safely accelerate study progression** with ECG capture and analysis; advanced imaging; neurophysiology and respiratory testing; and advanced bioanalytical and biomarker labs
- **Set a foundation for later phase success** by accelerating and simplifying advancing your molecule to the next phase — from first-in-human studies all the way to marketing authorization

Learn more about how IQVIA can customize a proactive, scalable delivery model best suited for your molecule to accelerate advancement to the next stage

IQVIA

CONTACT US

iqvia.com/earlyphase